What is ENDRA Life Sciences?
ENDRA Life Sciences, founded in 2009 and headquartered in Ann Arbor, Michigan, is dedicated to the early detection of liver disease. The company's focus on developing advanced diagnostic tools aims to address a critical unmet need in healthcare, potentially revolutionizing patient outcomes through timely and accurate identification of hepatic conditions. The enterprise-level funding suggests a strong market validation for its innovative approach.
How much funding has ENDRA Life Sciences raised?
ENDRA Life Sciences has raised a total of $27.9M across 4 funding rounds:
Stock Offering
$8.4M
Debt
$150K
Private Equity
$4.9M
Private Equity
$14.4M
Stock Issuance/Offering (2017): $8.4M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Private Equity (2025): $4.9M, investors not publicly disclosed
Private Equity (2025): $14.4M, investors not publicly disclosed
Key Investors in ENDRA Life Sciences
PPP
Public-Private Partnership
What's next for ENDRA Life Sciences?
With the recent influx of capital, ENDRA Life Sciences is poised for a significant scaling of its operations. This strategic backing is expected to fuel further research and development, enhance manufacturing capabilities, and accelerate market penetration. The company's trajectory indicates a move towards broader commercialization, aiming to establish its diagnostic solutions as a standard of care in liver disease screening.
See full ENDRA Life Sciences company page
